Evaluation of Anemia Medication Use in One-Day Care Patients with Chronic Kidney Disease at the Hemodialysis Unit of RSUD Dr. Achmad Mochtar Bukittinggi
DOI:
https://doi.org/10.35451/jfm.v9i1.3662Keywords:
Chronic Kidney Disease, Hemodialysis, Renal Anemia, Drug Rationality, Clinical PharmacyAbstract
Background: Chronic Kidney Disease (CKD) is a progressive impairment of renal function that frequently triggers renal anemia complications due to decreased erythropoietin hormone production. At RSUD Dr. Achmad Mochtar Bukittinggi, the service load of the Hemodialysis Unit is exceptionally high, making the evaluation of anemia therapy rationality crucial to ensure treatment efficacy. Objective: To evaluate patient characteristics, drug use patterns, and the level of drug use rationality for anemia therapy in One Day Care CKD patients undergoing hemodialysis. Methods: This descriptive observational study with a prospective approach involved 120 end-stage CKD respondents in January 2026. Data were collected through structured interviews and medical data verification. Results: The findings showed that respondents were predominantly male (59.17%), with the highest age group being 56–65 years old (30.83%). The therapeutic pattern indicated 100% erythropoietin use, 90.00% folic acid, 5.83% blood booster tablets, and 1.67% Sangobion. Rationality evaluation based on the 4T indicators (Right Patient, Right Drug, Right Indication, Right Dosage) demonstrated that correct patient, drug, and indication reached 100%. However, dosage accuracy was only 10.00%, where 90.00% of patients received a folic acid dose of 1–3 mg/day, which falls below the hospital's Clinical Practice Guidelines (CPG) standard of 5 mg/day. Conclusion: Overall, anemia therapy was appropriate regarding the right patient, right drug, and right indication, but requires significant correction in the folic acid dosage regimen.
Downloads
References
[1] DiPiro JT, Wells BG, Schwinghammer TL, DiPiro CV. Pharmacotherapy Handbook. 10th ed. McGraw-Hill Education; 2017.
[2] PERNEFRI. Konsensus Manajemen Anemia pada Penyakit Ginjal Kronik. 2nd ed. Perhimpunan Nefrologi Indonesia; 2011.
[3] KDIGO. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2025.
[4] Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med. 2021;8:1-14.
[5] Salwani D, Syukri M, Abdullah A. Tinjauan Pustaka Anemia pada Penyakit Ginjal Kronis. Jurnal Kedokteran Syiah Kuala. 2016;16(2):31-8.
[6] Akuba J, Panai M, Tuiyo SFR, Naue CR. Gambaran Tatalaksana Terapi Anemia Pada Pasien Gagal Ginjal Kronik di Rumah Sakit Toto Kabila. Jurnal Farmasi dan Kesehatan. 2023;1(1):63-9.
[7] SKI. Survei Kesehatan Indonesia (SKI) Dalam Angka. Kementerian Kesehatan RI; 2023.
[8] Kepmenkes. PNPK Tatalaksana Penyakit Ginjal Kronik. Kementerian Kesehatan RI; 2023.
[9] Sato Y, Fujimoto S, Konta T, Iseki K. Anemia as a Risk Factor for All-Cause Mortality: Obscure Synergic Effect of Chronic Kidney Disease. Clin Exp Nephrol. 2017;21(5):860-8.
[10] Zhao L, Hu C, Cheng J, Zhang P, Jiang H, Chen J. Hemoglobin Variability and All-Cause Mortality in Hemodialysis Patients: A Systematic Review and Meta-Analysis. Hemodial Int. 2020;24(2):189-98.
[11] Ferdina AR. Anemia pada Penyakit Ginjal Kronik. BRIN; 2023.
[12] Riskesdas. Laporan Provinsi Sumatera Barat Riskesdas 2018. LPB; 2018.
[13] Insani N, Zulfiani N, Yusransyah Y. Analisis Terapi Anemia Pada Pasien Gagal Ginjal Kronik di RSUD Dr. Dradjat Prawiranegara Tahun 2022. Jurnal Farmasi Indonesia. 2024;13(1):68-74.
[14] Megawati S, Restudiarti A, Kurniasih S. Evaluasi Penggunaan Obat Anemia Pada Pasien Ginjal Kronik yang Menjalani Hemodialisa di Rumah Sakit Umum Kabupaten Tangerang Tahun 2018. Jurnal Farmagazine. 2020;7(2):43-8.
[15] KDIGO. Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2023;13(1):1-140.
[16] DiPiro JT, Wells BG, Schwinghammer TL, DiPiro CV. Pharmacotherapy A Pathophysiologic Approach. McGraw-Hill Education; 2018.
[17] Tuloli TS, Madania M, Mustapa MA, Tuli EP. Evaluasi Penggunaan Obat Pada Pasien Gagal Ginjal Kronik Yang Menjalani Hemodialisis Di RSUD Toto Kabila Periode 2017-2018. Jurnal Ilmu Farmasi. 2019;8(2):25-30.
[18] Rahma N, Pawestri D, Novitasari D. Perbandingan Terapi Metformin dan Insulin Pada Pasien Chronic Kidney Disease (CKD). Jurnal Penelitian Kesehatan. 2024;8:1197-203.
[19] Kurniawan JA, Hakam A. Evaluation of Renal Anemia Therapy in Chronic Kidney Disease Patients Undergoing Hemodialysis in Hospital. Journal Global Health Research. 2026;8(1):155-62.
[20] Sumitra J, Jannah M, Darmirani Y. Analisis Implementasi Standar Pelayanan Kefarmasian Di Rumah Sakit Granmed Lubuk Pakam. Jurnal Farmasimed (JFM). 2026 Apr 30;8(2):915-20.
[21] Jannah M, Sari YO, Almasdy D. Kajian Kejadian Efek Samping Obat (ESO) pada Pasien Geriatri di Ruangan Rawat Inap Interne Sebuah Rumah Sakit Swasta di Kota Bukittinggi Sumatera Barat. Jurnal Farmasimed (JFM). 2024 Apr 30;6(2):178-85.
[22] Sari YO, Almasdy D, Fitri A. Potensi Interaksi Obat pada Pasien Gagal Ginjal Kronis yang Menjalani Hemodialisis. Jurnal Farmasimed (JFM). 2024;7(1):45-52.
[23] Lestari P, Rahmawati I. Hubungan Tingkat Kepatuhan Minum Obat terhadap Capaian Terapi Pasien Kronis. Jurnal Farmasimed (JFM). 2025;7(2):210-218.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Miftahul Jannah, Rido Farnandi, Jhoti Sumitra, Linda Hevira, Puteri Angeli
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
